information about syndrome of liberations of cytokins in oncological patients

Clinical Presentation: Cytokine release syndrome (CRS) in oncological patients typically presents with fever (temperature ≥38°C), chills, hypotension, hypoxia, and elevated liver enzymes, though fever may be masked by interventions like antipyretics or immunosuppressants. Severe systemic manifestations can include cardiac dysfunction, neurologic toxicity including immune effector cell-associated neurotoxicity syndrome (ICANS), and haemophagocytic lymphohistiocytosis (HLH), which carries a risk of severe bleeding. Early onset of fever or persistent fever after 24 hours of symptomatic treatment, high pre-infusion tumor burden, and active infections are risk factors for severe CRS. The clinical features may overlap with infection, necessitating careful evaluation to differentiate infectious causes from CRS as CRS can also co-occur with infections and increase fatal risk. Neurologic symptoms in concurrent ICANS may manifest as confusion, seizures, and encephalopathy and should be assessed distinctly from CRS manifestations. Laboratory markers often show elevated inflammatory cytokines such as IL-6, soluble IL-2 receptor, TNF-α, and IL-10 alongside systemic inflammatory response indicators like elevated C-reactive protein (CRP) and lymphopenia (Fevers, hypotension, hypoxia, and organ toxicities) SmPC CARVYKTI,SmPC Tepkinly,SmPC TepkinlySantomasso et al. 2021Synnott et al. 2025Cui et al. 2025Sato et al. 2026Raddatz et al. 2026.

Diagnosis: Diagnosis is clinical and based on the American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading criteria, which classify CRS severity from Grade 1 (mild, fever only) to Grade 4 (life-threatening with requirements for ventilatory or vasopressor support). Diagnosis requires ruling out infections and other causes for symptoms through blood cultures, inflammatory markers (CRP, procalcitonin), and cytokine profiling when available. Imaging may assist in evaluating organ involvement. Early recognition relies on vigilance for fever and systemic signs post-immunotherapy infusion; neurologic symptoms prompt separate ICANS assessment. Evaluation for HLH is recommended in severe or refractory CRS. The diagnostic process integrates clinical presentation, laboratory findings, and exclusion of infectious or other differential diagnoses SmPC CARVYKTI,NICE CG151,NICE CKSArvanitis et al. 2025Santomasso et al. 2021Cui et al. 2025.

Management: Management is stratified according to CRS grade, emphasizing early intervention and supportive care. For Grade 1 CRS, supportive measures such as antipyretics and intravenous hydration are recommended, with tocilizumab considered if symptoms persist or worsen. Grades 2-4 involve escalating care including tocilizumab (typically 8 mg/kg IV, max 800 mg) administered over one hour, repeated every 8 hours up to a maximum of 3 doses in 24 hours (not exceeding 4 total doses). Corticosteroids like dexamethasone or methylprednisolone are introduced at Grade 2 or higher especially if refractory to tocilizumab or for concurrent neurologic toxicity. In cases with no improvement, higher corticosteroid doses or alternative immunosuppressants (including other anti-cytokine therapies) may be considered. Vasopressors and oxygen support including high-flow nasal cannula or mechanical ventilation may be required in severe cases. Patients should be closely monitored at qualified centres for at least 14 days post-infusion, with instructions for immediate medical attention should symptoms occur. If CRS is refractory, alternative anti-cytokine agents and therapies aimed at CAR-T cell elimination may be indicated. Use of granulocyte-macrophage colony stimulating factor (GM-CSF) should be avoided during active CRS due to risk of exacerbation. The management approach should balance effective CRS control while minimizing impairment of immunotherapy efficacy. Discontinuation of causative agents such as epcoritamab may be warranted in persistent or recurrent high-grade CRS. For concurrent ICANS, corticosteroids are essential, and anti-cytokine therapy should be tailored to avoid worsening neurotoxicity SmPC CARVYKTI,SmPC Tepkinly,SmPC TepkinlySantomasso et al. 2021Arvanitis et al. 2025Sato et al. 2026.

Additional Considerations: Differentiation from neutropenic sepsis is critical, as both conditions can present similarly and may co-exist in oncological patients receiving chemotherapy. Neutropenic sepsis requires immediate empiric antibiotic therapy and supportive care following sepsis protocols. CRS requires immunomodulatory treatment rather than antimicrobial therapy unless concurrent infection is confirmed. The risk of infection should be minimized before immunotherapy infusion, and active infections must be resolved. Detailed patient counselling on symptom recognition and rapid access to specialist care is essential NICE CG151,NICE CKSNICE CG151 2012(NICE CKS, Neutropenic sepsis).